Addition of Myeloablative Doses of Total Marrow Irradiation (TMI) to Myeloablative Fludarabine/Busulfan Conditioning for Allogeneic HSCT in Patients with High-Risk AML, CML, or Myelodysplastic Syndrome: A Phase II Clinical Trial
- Resource Type
- Article
- Source
- Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p4897-4897, 1p
- Subject
- Language
- ISSN
- 00064971; 15280020